actavis inc (ACT) Details

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. The company offers its products for various therapeutic categories, such as cardiovascular, dermatology, urology, women’s health, oncology, pregnancy prevention, hormones and synthetic substitutes, anti-infective agents, central nervous system, pain management, depression, hypertension, attention-deficit/hyperactivity disorder, and smoking cessation. It operates through three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties’ brand products. This segment offers various dosage forms, such as oral solids, semi-solids, liquids, gels, transdermals, injectables, inhalation, and oral transmucosals. The Actavis Specialty Brands segment promotes and co-promotes Rapaflo, Gelnique, Crinone, Trelstar, Generess Fe, Androderm, Kadian, Crinone, AndroGel, INFeD, and sodium ferric gluconate branded products; and markets its products through sales professionals, as well as sells various non-promoted products. The Anda Distribution segment distributes generic and selected brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians’ offices. Actavis, Inc., sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors; hospitals, clinics, mail order, and government agencies; and managed healthcare providers. The company was formerly known as Watson Pharmaceuticals, Inc. and changed its name to Actavis, Inc. in January 2013. Actavis, Inc. was founded in 1983 and is headquartered in Parsippany, New Jersey.

actavis inc (ACT) Top Compensated Officers